ClinicalTrials.gg
CompletedNCT02992743Updated Apr 11, 2023Results posted

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

A Phase 2 interventional study of letetresgene autoleucel (GSK3377794) and Cyclophosphamide in Neoplasms, sponsored by GlaxoSmithKline. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-11.

Primary conditionLiposarcoma, MyxoidRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Liposarcoma, Myxoid
Why
  1. The study's title name Liposarcoma, Myxoid, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Liposarcoma, Myxoid with a site in United States — 7 open to participants now, 13 under way, none of them phase 3. Liposarcoma, Myxoid · United States.

Enrollment
17th of 28
23 · median 26
Started
2016
the only one that year
Phase 2
9 of 29
none open now
Registered
7th of 29
by date
Lead sponsor
1 of 29
GlaxoSmithKline

Among the 29 studies in Liposarcoma, Myxoid with a site in United States, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 2, and was the 7th registered.

Liposarcoma, Myxoid

40 studies on the registry are indexed under Liposarcoma, Myxoid; 12 are open to participants now.

Browse Liposarcoma, Myxoid studies →

Open to participants now

7 of the 29 studies in Liposarcoma, Myxoid with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Liposarcoma, Myxoid studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Liposarcoma, Myxoid with a site in United States, or all of them as a file.
02

Study summary

This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.

Read the detailed description

New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using adoptively transferred T-cells directed against NY-ESO-1/LAGE-1a have shown objective responses. Letetresgene autoleucel (GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor (TCR) engineered T-cells. This protocol investigates Letetresgene autoleucel treatment in Human Leukocyte Antigen (HLA)-A*02+ participants with NY-ESO1+ advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.

03

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Myxoid/ round cell liposarcoma
  • Letetresgene autoleucel
  • Immuno-oncology
  • T Cell Receptor
  • Leukapheresis
  • NY-ESO-1
  • Adoptive TCR T-cell therapy
04

In context

Liposarcoma, Myxoid Reclassified

40 studies on the registry are indexed under Liposarcoma, Myxoid; 12 are open to participants now.

This study's enrollment of 23 is below the median of 30 across 36 interventional studies indexed under Liposarcoma, Myxoid.

Browse Liposarcoma, Myxoid studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Liposarcoma, Myxoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is greater than equal to (>=)18 years of age at the time of signing the study .
  • Participant has a diagnosis of advanced ( or inoperable) high grade myxoid liposarcoma / myxoid round cell liposarcoma confirmed histologically and by the presence of the reciprocal chromosomal translocation t(12;16) (q13;p11) or t(12; 22) (q13;q12).
  • Participant has according to v1.1 criteria.
  • Participant must have previously received or be intolerant to anthracycline based therapy for advanced (metastatic or inoperable) disease.
  • Participants who received /adjuvant anthracycline based therapy and progressed within 6 months of completion of therapy will be eligible.
  • Participant must be HLA A*02:01, HLA A*02:05 and/or HLA-A*02:06 positive.
  • Participant's tumor (either the most recent or a fresh biopsy) is positive for NY-ESO-1 expression by a designated central laboratory.
  • Participant has an (ECOG) Performance Status 0-1.
  • Participant has a >=45%.
  • Participant is fit for apheresis and has adequate venous access for the cell collection.
  • Participants must satisfy pregnancy and requirements per protocol and have adequate organ function per protocol specified values.

Exclusion criteria

Exclusion Criteria:

  • Any previous gene therapy using an integrating vector.
  • Any previous hematopoietic stem cell transplant.
  • Participant has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
  • Participant has history of chronic or recurrent (within the last year prior to screening) severe or immune mediated disease requiring or other treatments.
  • Participant has known active brain or .
  • Participant has other prior that is not in complete remission.
  • Participant has uncontrolled intercurrent illness including, but not limited to:
  • (i) Ongoing or active infection.
  • (ii) cardiac disease
  • (iii) Interstitial lung disease (participants with existing pneumonitis as a result of radiation are not excluded, however, participants must not be oxygen dependent).
  • Participant has active infection with (HIV), virus (HBV), ), virus (HCV) or human T-lymphotropic virus (HTLV).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    letetresgene autoleucel (GSK3377794)

    Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.

    Drug: letetresgene autoleucel (GSK3377794) · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment

    Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.

    Time frame: Up to 24 months

  2. Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment

    The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by the investigator per RECIST v1.1 Criteria.

    Time frame: Up to 24 months

Secondary outcomes

  1. Time to Response (TTR) Assessed by Investigator

    Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

    Time frame: Up to 24 months

  2. Duration of Response (DOR) Assessed by Investigator

    Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

    Time frame: Up to 24 months

  3. Progression Free Survival (PFS) Assessed by Investigator

    Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by investigator per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

    Time frame: Up to 24 months

  4. Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer Assessment

    The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by independent reviewer per RECIST v1.1 criteria.

    Time frame: Up to 24 months

  5. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer

    Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via independent reviewer assessment per RECIST v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.

    Time frame: Up to 24 months

  6. Time to Response (TTR) Assessed by Independent Reviewer

    Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

    Time frame: Up to 24 months

  7. Duration of Response (DOR) Assessed by Independent Reviewer

    Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

    Time frame: Up to 24 months

  8. Progression Free Survival (PFS) Assessed by Independent Reviewer

    Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by independent reviewer per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

    Time frame: Up to 24 months

  9. Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is defined as any untoward medical occurrence that, at any dose can result in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth or is medically significant or requires intervention to prevent one or the outcomes listed above.

    Time frame: Up to 24 months

  10. Number of Participants With Adverse Event of Special Interest (AESI)

    An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. The AESI included events of Cytokine release syndrome (CRS), Haematopoietic cytopenias (including pancytopenia and aplastic anaemia), Graft versus host disease (GvHD), Immune Effector-Cell Associated Neurotoxicity Syndrome (ICANS), and Guillain-Barre syndrome.

    Time frame: Up to 24 months

  11. Number of Participants With Any Grade Increase in Hematology Results at Worst-case Post-baseline

    Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets, leukocytes. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.

    Time frame: Up to 24 months

  12. Number of Participants With Any Grade Increase in Clinical Chemistry Results at Worst-case Post-baseline

    Blood samples were collected for the analysis clinical chemistry parameters: glucose, albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, sodium, phosphate, calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.

    Time frame: Up to 24 months

  13. Number of Participants With Replication Competent Lentivirus (RCL)

    RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).

    Time frame: Day 1 (pre-infusion), and at Week 12, Week 24, and 1 year post-infusion

  14. Number of Participants With Insertional Oncogenesis

    Peripheral blood mononuclear cells (PBMC) samples were collected for monitoring insertional oncogenesis by PCR for gene modified cells in the blood. DNA from participant identified with \>1% PBMC at \>=1 year post T-cell infusion was sent for integration site analysis. Integration site analysis was used to assess the possibility of insertional oncogenesis. Participants with insertional oncogenesis were participants with any clones representing \>20% of the total.

    Time frame: Up to 2 years

  15. Number of Participants With Positive Anti-drug Antibodies (ADAs)

    Serum samples were collected to analyze for the presence of ADAs using validated immunoassays.

    Time frame: Up to 24 Months

  16. Maximum Transgene Expansion (Cmax) of GSK3377794

    Cmax was defined as peak cell expansion during the interventional phase. Blood samples were collected to measure Cmax.

    Time frame: Day 2 to Day 15

  17. Time to Cmax (Tmax)

    Tmax was defined as time to peak cell expansion during the interventional phase. Blood samples were collected to measure Tmax.

    Time frame: Day 2 to Day 15

  18. Area Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794

    Area under the cell expansion-time curve from first T-cell infusion to Day 28. Blood samples were collected to measure AUC (0-28 days).

    Time frame: Up to 28 days

  19. Change From Baseline in Electrocardiogram (ECG) Parameters- PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval and RR Interval

    Triplicate 12-Lead ECGs were collected at baseline visit and single ECGs at other timepoints. At each time point during the study ECG was taken using an ECG machine that automatically calculates the heart rate and measured the PR interval, QRS duration, QTcB, QTcF intervals, RR interval and uncorrected QT interval. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.

    Time frame: Baseline, Day 1, Day 4 and Day 8

  20. Change From Baseline in ECG Mean Heart Rate

    Single 12-lead ECG was to be obtained at designated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.

    Time frame: Baseline, Day 1 (Pre-dose), Day 4 and Day 8

08

Results

Posted Nov 28, 2022

Participant flow

This was an open-label study evaluating the safety and tolerability of autologous T-Cells expressing enhanced T-cell receptors (TCRs) specific for New York esophageal squamous cell carcinoma (NY-ESO)-1 (letetresgene autoleucel, lete-cel, GSK3377794) in Human Leukocyte Antigen (HLA)-A\*02:01, HLA-A\*02:05 and/or HLA-A\*02:06 participants with Advanced Myxoid/ Round Cell Liposarcoma.

Participant flow — Overall Study
MilestoneReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Started1310
Received t-cell infusion1010
Completed98
Not completed42
Withdrew: Withdrawal by subject11
Withdrew: Death-prior to t-cell infusion10
Withdrew: Did not meet inclusion/exclusion10
Withdrew: No measurable disease10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryOverall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment

Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.

Time frame:
Up to 24 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
Percentage of participantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment20 (2.5 to 55.6)40 (12.2 to 73.8)
PrimaryBest Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment

The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by the investigator per RECIST v1.1 Criteria.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Complete Response (CR)00
Partial Response (PR)24
Stable Disease (SD)85
Progressive Disease (PD)01
Not Evaluable (NE)00
SecondaryTime to Response (TTR) Assessed by Investigator

Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

Time frame:
Up to 24 months
Reported as:
Median · Months
Time to Response (TTR) Assessed by Investigator
MonthsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Time to Response (TTR) Assessed by Investigator1.856 (0.920 to 2.793)1.938 (1.889 to 2.366)
SecondaryDuration of Response (DOR) Assessed by Investigator

Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

Time frame:
Up to 24 months
Reported as:
Median · Months
Duration of Response (DOR) Assessed by Investigator
MonthsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Duration of Response (DOR) Assessed by Investigator5.31 (1.87 to 8.74)7.47 (6.01 to NA)
SecondaryProgression Free Survival (PFS) Assessed by Investigator

Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by investigator per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

Time frame:
Up to 24 months
Reported as:
Median · Months
Progression Free Survival (PFS) Assessed by Investigator
MonthsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Progression Free Survival (PFS) Assessed by Investigator5.36 (2.00 to 11.50)8.74 (0.89 to NA)
SecondaryBest Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer Assessment

The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by independent reviewer per RECIST v1.1 criteria.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer Assessment
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Complete Response (CR)00
Partial Response (PR)24
Stable Disease (SD)83
Progressive Disease (PD)00
Not Evaluable (NE)03
SecondaryOverall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer

Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via independent reviewer assessment per RECIST v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.

Time frame:
Up to 24 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer
Percentage of participantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer20 (2.5 to 55.6)40 (12.2 to 73.8)
SecondaryTime to Response (TTR) Assessed by Independent Reviewer

Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.

Time frame:
Up to 24 months
Reported as:
Median · Months
Time to Response (TTR) Assessed by Independent Reviewer
MonthsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Time to Response (TTR) Assessed by Independent Reviewer2.366 (1.840 to 2.891)1.889 (1.413 to 1.938)
SecondaryDuration of Response (DOR) Assessed by Independent Reviewer

Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

Time frame:
Up to 24 months
Reported as:
Median · Months
Duration of Response (DOR) Assessed by Independent Reviewer
MonthsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Duration of Response (DOR) Assessed by Independent ReviewerNA (NA to NA)7.16 (4.57 to NA)
SecondaryProgression Free Survival (PFS) Assessed by Independent Reviewer

Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by independent reviewer per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.

Time frame:
Up to 24 months
Reported as:
Median · Months
Progression Free Survival (PFS) Assessed by Independent Reviewer
MonthsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Progression Free Survival (PFS) Assessed by Independent Reviewer4.67 (2.79 to NA)9.03 (5.32 to NA)
SecondaryNumber of Participants With Serious Adverse Events (SAEs) and Non-SAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is defined as any untoward medical occurrence that, at any dose can result in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth or is medically significant or requires intervention to prevent one or the outcomes listed above.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
SAEs57
Non-SAEs1310
SecondaryNumber of Participants With Adverse Event of Special Interest (AESI)

An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. The AESI included events of Cytokine release syndrome (CRS), Haematopoietic cytopenias (including pancytopenia and aplastic anaemia), Graft versus host disease (GvHD), Immune Effector-Cell Associated Neurotoxicity Syndrome (ICANS), and Guillain-Barre syndrome.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event of Special Interest (AESI)
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Participants with any AESI1010
Cytokine release syndrome610
Haematopoietic cytopenias (including pancytopenia and aplastic anaemia)1010
SecondaryNumber of Participants With Any Grade Increase in Hematology Results at Worst-case Post-baseline

Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets, leukocytes. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Any Grade Increase in Hematology Results at Worst-case Post-baseline
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Hemoglobin Anemia910
Lymphocyte count decreased1010
Neutrophils1010
Platelets910
Leukocytes1010
SecondaryNumber of Participants With Any Grade Increase in Clinical Chemistry Results at Worst-case Post-baseline

Blood samples were collected for the analysis clinical chemistry parameters: glucose, albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, sodium, phosphate, calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Any Grade Increase in Clinical Chemistry Results at Worst-case Post-baseline
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Glucose Hyperglycemia58
Glucose Hypoglycemia14
Albumin99
Alkaline Phosphatase46
ALT77
AST88
Bilirubin32
Creatinine42
Potassium Hyperkalemia11
Potassium Hypokalemia59
Magnesium Hypermagnesemia52
Magnesium Hypomagnesemia26
Phosphate910
Sodium Hypernatremia21
Sodium Hyponatremia89
Calcium Corrected for Albumin Hypercalcemia21
Calcium Corrected for Albumin Hypocalcemia17
SecondaryNumber of Participants With Replication Competent Lentivirus (RCL)

RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).

Time frame:
Day 1 (pre-infusion), and at Week 12, Week 24, and 1 year post-infusion
Reported as:
Count of participants · Participants
Number of Participants With Replication Competent Lentivirus (RCL)
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Number of Participants With Replication Competent Lentivirus (RCL)00
SecondaryNumber of Participants With Insertional Oncogenesis

Peripheral blood mononuclear cells (PBMC) samples were collected for monitoring insertional oncogenesis by PCR for gene modified cells in the blood. DNA from participant identified with \>1% PBMC at \>=1 year post T-cell infusion was sent for integration site analysis. Integration site analysis was used to assess the possibility of insertional oncogenesis. Participants with insertional oncogenesis were participants with any clones representing \>20% of the total.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants With Insertional Oncogenesis
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Number of Participants With Insertional Oncogenesis00
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADAs)

Serum samples were collected to analyze for the presence of ADAs using validated immunoassays.

Time frame:
Up to 24 Months
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADAs)
ParticipantsReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Number of Participants With Positive Anti-drug Antibodies (ADAs)00
SecondaryMaximum Transgene Expansion (Cmax) of GSK3377794

Cmax was defined as peak cell expansion during the interventional phase. Blood samples were collected to measure Cmax.

Time frame:
Day 2 to Day 15
Reported as:
Geometric mean · Copies per microgram genomic DNA
Maximum Transgene Expansion (Cmax) of GSK3377794
Copies per microgram genomic DNAReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Maximum Transgene Expansion (Cmax) of GSK337779466991.71 ± 127.0108485.91 ± 53.4
SecondaryTime to Cmax (Tmax)

Tmax was defined as time to peak cell expansion during the interventional phase. Blood samples were collected to measure Tmax.

Time frame:
Day 2 to Day 15
Reported as:
Median · Days
Time to Cmax (Tmax)
DaysReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Time to Cmax (Tmax)2 (2 to 13)4 (2 to 15)
SecondaryArea Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794

Area under the cell expansion-time curve from first T-cell infusion to Day 28. Blood samples were collected to measure AUC (0-28 days).

Time frame:
Up to 28 days
Reported as:
Geometric mean · Days*copies per microgram genomic DNA
Area Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794
Days*copies per microgram genomic DNAReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Area Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794727135.6 ± 223.91142798.27 ± 70.7
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters- PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval and RR Interval

Triplicate 12-Lead ECGs were collected at baseline visit and single ECGs at other timepoints. At each time point during the study ECG was taken using an ECG machine that automatically calculates the heart rate and measured the PR interval, QRS duration, QTcB, QTcF intervals, RR interval and uncorrected QT interval. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.

Time frame:
Baseline, Day 1, Day 4 and Day 8
Reported as:
Mean · Milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Parameters- PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval and RR Interval
Milliseconds (msec)Reduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
PR Interval, BASELINE152.9 ± 14.59142 ± 12.72
PR Interval, DAY 1-2.3 ± 8.66-2.2 ± 9.82
PR Interval, DAY 4-10.7 ± 17.18-4 ± 12.96
PR Interval, DAY 8-8.1 ± 14.91 ± 9.32
QRS Duration, BASELINE91.2 ± 16.5386.1 ± 15.01
QRS Duration, DAY 12.8 ± 18.870.9 ± 6.49
QRS Duration, DAY 42.3 ± 20.430.8 ± 5.75
QRS Duration, DAY 8-2.7 ± 25.75-1 ± 5.86
QT Interval, BASELINE401.1 ± 11.71389.3 ± 33.57
QT Interval, DAY 1-6.4 ± 23.51-8.1 ± 33.74
QT Interval, DAY 4-49.4 ± 38.59-72.5 ± 47.65
QT Interval, DAY 8-16.7 ± 21.63-4.4 ± 43.41
QTcB Interval, BASELINE427 ± 4.24423.3 ± 19.35
QTcB Interval, DAY 128 ± NA36.3 ± 34.03
QTcB Interval, DAY 410 ± 24.048 ± 25.46
QTcB Interval, DAY 81 ± NA47 ± 50.27
QTcF Interval, BASELINE429.9 ± 23.75425.3 ± 16.18
QTcF Interval, DAY 1-10.1 ± 21.061.3 ± 17.36
QTcF Interval, DAY 4-25.3 ± 36.623.3 ± 31.1
QTcF Interval, DAY 8-7.5 ± 22.6316.2 ± 39.96
RR Interval, BASELINE842.6 ± 144.62807.6 ± 166.39
RR Interval, DAY 1-15.8 ± 98.775.3 ± 43.1
RR Interval, DAY 4-162.5 ± 179.21-188 ± 11.31
RR Interval, DAY 8-71.6 ± 109.66-138.5 ± 77.72
SecondaryChange From Baseline in ECG Mean Heart Rate

Single 12-lead ECG was to be obtained at designated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.

Time frame:
Baseline, Day 1 (Pre-dose), Day 4 and Day 8
Reported as:
Mean · Beats per minute (beats/minute)
Change From Baseline in ECG Mean Heart Rate
Beats per minute (beats/minute)Reduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
BASELINE73.0 ± 12.3478.0 ± 20.06
DAY 11.6 ± 10.084.8 ± 14.20
DAY 420.1 ± 16.3438.9 ± 21.95
DAY 85.4 ± 12.729.1 ± 16.37

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 30 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reduced Lymphodepletion Dose Plus GSK33777945/13 (38.5%)5/13 (38.5%)13/13 (100%)
Standard Lymphodepletion Dose Plus GSK33777940/10 (0%)7/10 (70%)10/10 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
Cytokine release syndromeImmune system disorders3/135/10
Rash maculo-papularSkin and subcutaneous tissue disorders0/133/10
PyrexiaGeneral disorders0/131/10
PneumoniaInfections and infestations0/131/10
Neutrophil count decreasedInvestigations0/131/10
Platelet count decreasedInvestigations1/131/10
Transaminases increasedInvestigations0/131/10
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/131/10
Pleural effusionRespiratory, thoracic and mediastinal disorders1/131/10
AnaemiaBlood and lymphatic system disorders1/130/10
Most frequent other events
Showing 10 of 178
Most frequent other events
EventReduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794
White blood cell count decreasedInvestigations7/1310/10
AnaemiaBlood and lymphatic system disorders6/139/10
NauseaGastrointestinal disorders8/138/10
PyrexiaGeneral disorders8/138/10
Neutrophil count decreasedInvestigations7/138/10
HypophosphataemiaMetabolism and nutrition disorders6/138/10
Lymphocyte count decreasedInvestigations10/137/10
FatigueGeneral disorders8/137/10
Platelet count decreasedInvestigations4/137/10
DiarrhoeaGastrointestinal disorders5/136/10

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Reduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794Total
Mean50.0 ± 6.7946.0 ± 11.6148.3 ± 9.19
Sex: Female, Male
Sex: Female, Male(Participants)Reduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794Total
Female639
Male7714
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Reduced Lymphodepletion Dose Plus GSK3377794Standard Lymphodepletion Dose Plus GSK3377794Total
Black or African American101
Other: More than one race101
White111021
09

Study locations

6 sites
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Nov 2021, 58 months.

Results were first posted in Nov 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2016
First posted
Dec 14, 2016
StartActual
Dec 6, 2016
Primary completionActual
Nov 1, 2021
CompletionActual
Mar 22, 2022
Results first posted
Nov 28, 2022
Last update
Apr 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02992743
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 14, 2016
Start date
Dec 6, 2016
Primary completion
Nov 1, 2021
Completion
Mar 22, 2022
Results posted
Nov 28, 2022
Last update
Apr 11, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letetresgene autoleucel

Start the discussion